VIDEO : Faire de l'argent dans les biotech (en anglais : Making Money in Biotech)

Série de 3 vidéos en anglais compréhensibles et intéressantes.

Making Money in Biotech, the JMP Securities Way - Part I: State of the Industry Mid Year Report

The biotech sector is driven by news flow, because it has the power to change the value of companies, and put (more) money in your wallet. Charles Duncan and Jean-Loup discuss the performance of the Biotech industry in 2008 to this day, and the potential impact of news to come in the remainder of this year in the coming months. Despite the very challenging conditions, biotech outperformed. Charles and Jean-Loup also touch on the industry's relative strength in the tough financial markets, and the increased M&A activity.

This interview was conducted at the NASDAQ Marketsite, on September 9th, 2008, in New York City.

Making Money in Biotech, the JMP Securities Way - Part II: Finding the Tipping Point

Which companies are likely to have news that can double the value your shares? Charles Duncan looks at the less obvious stock picks that could provide you with the most bang for your buck. His equation for determining the best opportunities incorporates variables such as lack of revenue (yes he means lack of), products that are owned outright and about to get significant clinical data, no FDA risk, and good cash position.

This interview was conducted at the NASDAQ Marketsite, on September 9th, 2008, in New York City.

Making Money in Biotech, the JMP Securities Way - Part III: A few Stock Picks

Allos, Cytokinetics, Orexigen, and Sangamo or just a few of JMP Securities stock picks for the end of the year. Charles Duncan explains how they are at a pivotal moment in their growth, and therefore best positioned to generate large returns for investors. Charles gives us some details about the company, the ongoing clinical trials, and the type of news we should expect in the months to come.

This interview was conducted at the NASDAQ Marketsite, on September 9th, 2008, in New York City.